Investigators report safety findings and statistically significant improvements in clinical measures of movement, PET Scans at 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement DisordersNeurologix's Phase I trial showed positive interim results in patients with Parkinson's disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.